Our Science | Clinical Pipeline

Sort by:

Indication

Molecule

Indication

Study

Line & Regimen

Indication:

Lung Cancer

Study: 
                  
Line & Regimen : 
              1L
              
                            dom + zim + chemo vs.
pembro + chemo
            
Phase 1/1b
Phase 2
Phase 3
Study: 
                  
Line & Regimen : 

              Stage III, unresectable, PD-L1≥1%
                            
                            dom + durvalumab vs. durvalumab
            
Phase 1/1b
Phase 2
Phase 3
Study: 
                  
Line & Regimen : 

              1L
                            
                            dom + zim ± quemli ± chemo 
            
Phase 1/1b
Phase 2
Phase 3
Study: 
                  
Line & Regimen : 

              1L, 2L
                            
                            dom ± zim ± etruma ± 
sacituzumab govitecan
            
Phase 1/1b
Phase 2
Phase 3
Study: 
                  
Line & Regimen : 

              1L, PD-L1 ≥ 50%
                            
                            dom + zim ± etruma vs. zim
            
Phase 1/1b
Phase 2
Phase 3
Study: 
                  
Line & Regimen : 

              2L+
                            
                            AB801 ± chemo + zim
            
Phase 1/1b
Phase 2
Phase 3

Indication:

Gastrointestinal Cancer

Study: 
                  
Line & Regimen : 
              1L
              
                            dom + zim + chemo vs.
nivo + chemo
            
Phase 1/1b
Phase 2
Phase 3
Study: 
                  
Line & Regimen : 

              1L
                            
                            dom ± zim ± FOLFOX
            
Phase 1/1b
Phase 2
Phase 3
Study: 
                  
Line & Regimen : 

              2L
                            
                            dom ± zim ± quemli
            
Phase 1/1b
Phase 2
Phase 3
Study: 
                  
Line & Regimen : 

              1L
                            
                            AB598 ± zim + chemo
            
Phase 1/1b
Phase 2
Phase 3

Indication:

Kidney Cancer

Study:

Line & Regimen :

2L+
cas

Phase 1/1b

Phase 2

Phase 3

Indication:

Pancreatic Cancer

Study: 
                  
Line & Regimen : 
              1L
              
                             quemli + gem/nab-pac vs. gem/nab-pac
            
Phase 1/1b
Phase 2
Phase 3
Study: 
                  
Line & Regimen : 

              1L
                            
                            quemli + zim + gem/nab-pac vs. quemli + gem/nab-pac
            
Phase 1/1b
Phase 2
Phase 3
Study: 
                  
Line & Regimen : 

              2L
                            
                            quemli + zim + gem/nab-pac
            
Phase 1/1b
Phase 2
Phase 3

Indication:

Colorectal Cancer

Study:

Line & Regimen :

2L
etruma + zim + FOLFOX* vs. FOLFOX*

Phase 1/1b

Phase 2

Phase 3

Study:

Line & Regimen :

3L
etruma + zim + FOLFOX* vs. rego

Phase 1/1b

Phase 2

Phase 3

Indication:

Head and Neck Cancer

Study:

Line & Regimen :

1L
dom + zim + chemo vs. zim + chemo

Phase 1/1b

Phase 2

Phase 3

Molecule:

Domvanalimab
(DOM)

FC-SILENT ANTI-TIGIT ANTIBODY

Indication:Gastrointestinal Cancer
Study:
                  
Line & Regimen :
              1L

              dom + zim + chemo vs.
nivo + chemo
            
Phase 1/1b
Phase 2
Phase 3
Indication:Gastrointestinal Cancer
Study:
                  
Line & Regimen :

              1L

              dom ± zim ± FOLFOX
            
Phase 1/1b
Phase 2
Phase 3
Indication:Gastrointestinal Cancer
Study:
                  
Line & Regimen :

              2L

              dom ± zim ± quemli
            
Phase 1/1b
Phase 2
Phase 3
Indication:Lung Cancer
Study:
                  
Line & Regimen :

              1L

              dom + zim + chemo vs. pembro + chemo
            
Phase 1/1b
Phase 2
Phase 3
Indication:Lung Cancer
Study:
                  
Line & Regimen :

              Stage III, unresectable, PD-L1≥1%

              dom + durvalumab vs. durvalumab
            
Phase 1/1b
Phase 2
Phase 3
Indication:Lung Cancer
Study:
                  
Line & Regimen :

              1L

              dom + zim ± quemli ± chemo
            
Phase 1/1b
Phase 2
Phase 3
Indication:Lung Cancer
Study:
                  
Line & Regimen :

              1L, 2L

              dom ± zim ± etruma ± sacituzumab govitecan
            
Phase 1/1b
Phase 2
Phase 3
Indication:Lung Cancer
Study:
                  
Line & Regimen :

              1L, PD-L1 ≥ 50%

              dom + zim ± etruma vs. zim
            
Phase 1/1b
Phase 2
Phase 3
Indication:Head and Neck Cancer
Study:
                  
Line & Regimen :

              1L

              dom + zim + chemo vs. zim + chemo
            
Phase 1/1b
Phase 2
Phase 3

Molecule:

Quemliclustat
(QUEMLI)

CD73 Inhibitor Small Molecule

Indication:Lung Cancer
Study:
                  
Line & Regimen :
              1L

              dom + zim ± quemli ± chemo
            
Phase 1/1b
Phase 2
Phase 3
Indication:GASTROINTESTINAL CANCER
Study:
                  
Line & Regimen :

              2L

              dom ± zim ± quemli
            
Phase 1/1b
Phase 2
Phase 3
Indication:Pancreatic Cancer
Study:
                  
Line & Regimen :

              1L

              quemli + gem/nab-pac vs. gem/nab-pac
            
Phase 1/1b
Phase 2
Phase 3
Indication:Pancreatic Cancer
Study:
                  
Line & Regimen :

              1L

              quemli + zim + gem/nab-pac vs. quemli + gem/nab-pac
            
Phase 1/1b
Phase 2
Phase 3
Indication:Pancreatic Cancer
Study:
                  
Line & Regimen :

              2L

              quemli + zim + gem/nab-pac
            
Phase 1/1b
Phase 2
Phase 3

Molecule:

Etrumadenant
(ETRUMA)

Dual A_2a/A_2b Adenosine Receptor Antagonist Small Molecule

Indication:Lung Cancer
Study:
                  
Line & Regimen :
              1L, PD-L1 ≥ 50%

              dom + zim ± etruma vs. zim
            
Phase 1/1b
Phase 2
Phase 3
Indication:Lung Cancer
Study:
                  
Line & Regimen :

              1L, 2L

              dom ± zim ± etruma ± sacituzumab govitecan
            
Phase 1/1b
Phase 2
Phase 3
Indication:Colorectal Cancer
Study:
                  
Line & Regimen :

              2L

              etruma + zim + FOLFOX* vs. FOLFOX*
            
Phase 1/1b
Phase 2
Phase 3
Indication:Colorectal Cancer
Study:
                  
Line & Regimen :

              3L

              etruma + zim + FOLFOX* vs. rego
            
Phase 1/1b
Phase 2
Phase 3

Clinical Pipeline

Explore More